Reported 6 days ago
Source: YAHOO
Reported 6 days ago
Source: YAHOO
Reported 6 days ago
Source: YAHOO
Reported 6 days ago
This week, the U.S. jobs report for August and earnings from Broadcom and Salesforce are key events in a trading week shortened by the Labor Day holiday. The labor market's potential weakness and interest rate cut expectations from the Federal Reserve are pivotal concerns, while Broadcom focuses on the growth of AI semiconductors following Nvidia's recent report. Additional market data and earnings reports, including from Figma and Nio, are also anticipated.
Source: YAHOO
Reported 6 days ago
HSBC analyst Rajesh Kumar upgraded Eli Lilly and Company (LLY) from Sell to Hold and increased the price target from $675 to $700, reflecting the company's progress with its oral weight-loss drug, which is expected to gain FDA approval in 2026. This follows a nearly 17% increase in share value since mid-August, after facing a YTD decline of over 5%. The majority of analysts now rate the stock as Buy, with a consensus price target suggesting a potential upside of 23%.
Source: YAHOO
Reported 6 days ago
Oppenheimer has raised its price target for Broadcom Inc. (NASDAQ:AVGO) from $305 to $325, maintaining an Outperform rating as the company prepares for its Q3 results. The analyst anticipates a strong performance driven by Broadcom's leadership in AI networking and custom AI ASICs, serving major clients like Google and Meta. This optimistic outlook aligns with Citi's recent projection of a $315 target and a strong contribution from AI-related revenues.
Source: YAHOO
Reported 6 days ago
Analysts continue to express confidence in Mastercard Inc. (NYSE:MA), highlighting its strong position in the global payments market as the trend towards digital transactions grows. With recommendations from various analysts maintaining Buy ratings and raising price targets, Mastercard is poised to benefit from its robust business model and innovative strategies in cybersecurity and emerging payment technologies. As a leader in the payment industry, Mastercard is expected to sustain its growth momentum, bolstered by consumer spending and a solid global presence.
Source: YAHOO
Reported 6 days ago
Alphabet Inc. (GOOGL) has announced a $9 billion investment in Virginia aimed at bolstering its cloud and AI infrastructure by 2026. The plan includes the construction of a new data center in Chesterfield County and expansions in Loudoun and Prince William counties, solidifying northern Virginia’s status as a data center hub. This investment comes amidst increasing competition in AI infrastructure, with other tech giants like Microsoft, Amazon, and Meta also making significant financial commitments in the sector.
Source: YAHOO
Reported 6 days ago
Piper Sandler has increased its price target for Amgen Inc. (NASDAQ:AMGN) from $328 to $342, while maintaining an Overweight rating. This adjustment follows the company's recent quarterly results, indicating that Amgen is well-prepared to handle the loss of exclusivity for denosumab, and is benefiting from strong performance across its commercial offerings and pipeline advancements.
Source: YAHOO
Reported 6 days ago
Bank of America Securities reaffirms its Hold rating on PDD Holdings Inc. (NASDAQ:PDD) while raising the price target to $141 from $120. Despite strong Q2 results exceeding expectations, concerns linger over the sustainability of profits due to high seasonality and competitive pressures. PDD, a major online commerce group in China, continues to expand its market presence, but analysts suggest that other AI stocks may offer better investment potential.
Source: YAHOO
Reported 6 days ago
BMO Capital analyst Evan Seigerman has maintained a 'Hold' rating on Bristol-Myers Squibb (NYSE:BMY), with a price target set at $47.00. While the company has shown solid prescription growth for its product Cobenfy, it is expected to fall short of revenue expectations for Q3 2025, adding uncertainty to forecasts. The analyst suggests that despite BMY's potential, other AI stocks may offer better investment upside.
Source: YAHOO
Reported 6 days ago
Jefferies has reaffirmed its Buy rating for CVS Health Corporation (NYSE:CVS), setting a price target of $80. The updated rating follows the company’s fiscal Q2 2025 results, where CVS reported an 8.4% increase in revenues to $98.9 billion. Additionally, UBS also upgraded its rating on CVS to Buy with a $79.00 target, highlighting the stock's current undervaluation. CVS operates across various segments, including healthcare benefits and pharmacy services, positioning it as a major player in the health solutions market.
Source: YAHOO
Reported 6 days ago
Gilead Sciences, Inc. (NASDAQ:GILD) has announced that it received marketing authorization from the European Commission for Yeytuo (lenacapavir), a twice-yearly injectable HIV-1 capsid inhibitor. This drug serves as a pre-exposure prophylaxis (PrEP) for adults and adolescents at high risk for HIV-1, making it the first and only option approved for use across the 27 EU member states. Gilead continues to focus on developing medicines for critical health needs across more than 35 countries.
Source: YAHOO
Reported 6 days ago
UBS has raised its price target for ConocoPhillips (NYSE:COP) from $116 to $123 while maintaining a Buy rating on the stock. This adjustment follows ConocoPhillips' fiscal Q2 2025 earnings announcement, where the company reported earnings per share of $1.56 and a strong cash flow. The company is recognized as a resilient low volatility stock in the oil and gas sector.
Source: YAHOO
Reported 6 days ago
Pfizer Inc. (NYSE:PFE) has received FDA approval for its supplemental Biologics License Application (sBLA) concerning the LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1), which is intended for adults 65 and older and younger individuals aged 5 to 64 with high-risk underlying conditions. The approval is based on extensive evidence showcasing the vaccine's safety and efficacy, including data from clinical trials for children aged 5 to 11.
Source: YAHOO
Reported 6 days ago
Bank of America Securities analyst Michael Funk has reiterated a Buy rating for AT&T Inc. (NYSE:T) with a price target of $34.00, citing the company's strong financial outlook and competitive positioning, particularly after its recent $23 billion acquisition of spectrum licenses from EchoStar. This acquisition is expected to enhance AT&T's broadband and wireless services, which are vital for its future growth. However, the report also mentions that certain AI stocks might present better investment opportunities.
Source: YAHOO
Reported 6 days ago
Verizon Communications Inc. (NYSE:VZ) is identified as a top undervalued stock with low volatility, as analyst Gregory Williams from TD Cowen maintains a Buy rating with a price target increase to $56. The company's management shows confidence in achieving EBITDA growth, bolstered by cost-saving strategies and strong service revenue. Additionally, Verizon’s AI integration in customer care is expected to enhance operational efficiency. Despite its potential, some analysts suggest other AI stocks may present better investment opportunities.
Source: YAHOO
Reported 6 days ago
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is currently viewed as a strong buy by analysts, with Bernstein's William Pickering maintaining a Buy rating and a price target of $95.00, while Evercore ISI's Cory Kasimov set a target of $110.00. The analyst consensus indicates a Strong Buy with a median price target suggesting a potential upside of 70.49%. The company focuses on developing treatments for serious and rare medical conditions.
Source: YAHOO
Reported 6 days ago
H.C. Wainwright has raised its price target for Summit Therapeutics Inc. (NASDAQ:SMMT) from $44 to $50, maintaining a Buy rating. The firm highlighted the positive results from Akeso’s HARMONi-A study, indicating that their drug ivonescimab outperforms Keytruda. Summit Therapeutics focuses on developing therapies for serious medical needs, particularly Clostridioides Difficile Infection (CDI).
Source: YAHOO
Reported 6 days ago
Citizens JMP analyst Andrew Boone has reiterated a Buy rating on Wix.com Ltd. (NASDAQ:WIX) with a price target of $200.00, following positive fiscal Q2 2025 results that highlighted significant revenue growth and strong bookings. The company's cloud-based website design platform continues to gain traction, evidenced by a 14% year-over-year increase in new cohort bookings. While Wix presents a solid investment opportunity, some analysts suggest that certain AI stocks may offer better upside potential.
Source: YAHOO
Reported 6 days ago
Canaccord Genuity analyst Joseph Vafi has reaffirmed a Buy rating for Strategy Inc. (NASDAQ:MSTR), setting a price target of $464. He noted that the company's recent preferred stock sales, which raised over $6 billion this year, highlight its success in the capital markets. Despite Bitcoin's volatility posing risks, Vafi considers MSTR to be one of the most innovative companies in his coverage, predicting an increase in firms adopting its Bitcoin-driven treasury strategy.
Source: YAHOO
Reported 6 days ago
Jefferies analyst Tycho Peterson reaffirmed a Buy rating on Exact Sciences Corporation (NASDAQ:EXAS) on August 21, with a price target set at $80.00. The company reported a record revenue of $811 million for Q2 2025, a 16% increase, and raised its revenue guidance. Exact Sciences specializes in cancer detection and offers tests like Cologuard for colorectal cancer screening. Despite its investment potential, some analysts suggest AI stocks may offer better returns.
Source: YAHOO
Reported 6 days ago
Stifel Nicolaus has reaffirmed its Buy rating for HubSpot, Inc. (NYSE:HUBS), setting a price target of $650 following the company's strong Q2 2025 earnings, which showed a 19% increase in total revenue to $760.9 million compared to the previous year. The report highlighted the company's solid subscription revenue growth and the innovative features of its software products designed for inbound marketing, customer service, and sales.
Source: YAHOO
Reported 6 days ago
Teva Pharmaceutical Industries Limited has announced the FDA approval and U.S. launch of Generic Saxenda, the first generic GLP-1 medication for weight loss, aimed at addressing the increasing demand in the U.S. market. This product is designed for adults with obesity and adolescents aged 12-17 who are overweight. This launch marks Teva's fifth first-to-market generic entry this year, further establishing its robust generics portfolio.
Source: YAHOO
Reported 6 days ago
BofA analyst Wamsi Mohan has reduced the price target for Nutanix, Inc. (NASDAQ:NTNX) from $95 to $93 while maintaining a Buy rating. The adjustment follows the company's strong fiscal Q4 results, which exceeded expectations, although a conservative outlook for fiscal year 2026 is anticipated. Despite the price target reduction, Nutanix has consistently surpassed operating margin guidance by a significant margin over the past three years.
Source: YAHOO